These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 32071339)

  • 1. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.
    Hu Z
    Sci Rep; 2020 Feb; 10(1):2815. PubMed ID: 32071339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
    Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
    Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
    Hu Z; Shen R; Campbell A; McMichael E; Yu L; Ramaswamy B; London CA; Xu T; Carson WE
    Cancer Immunol Res; 2018 Jun; 6(6):671-684. PubMed ID: 29622581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
    Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
    Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
    Front Immunol; 2019; 10():1149. PubMed ID: 31178870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
    Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
    Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer.
    Raftery MJ; Franzén AS; Radecke C; Boulifa A; Schönrich G; Stintzing S; Blohmer JU; Pecher G
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
    Han Y; Xie W; Song DG; Powell DJ
    J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
    Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
    Front Immunol; 2020; 11():573823. PubMed ID: 33072116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models.
    Yang M; Guan T; Chen CF; He LF; Wu HM; Zhang RD; Li Y; Lin YC; Zeng H; Wu JD
    J Immunother; 2023 Oct; 46(8):285-294. PubMed ID: 37584622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
    Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
    Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of non-genetically modified, CAR-like, NK cells.
    Coënon L; Rigal E; Courot H; Multrier C; Zemiti S; Lambour J; Pugnière M; de Toledo M; Bossis G; Cartron G; Robert B; Martineau P; Fauvel B; Presumey J; Villalba M
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39029925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer.
    Cao B; Liu M; Huang J; Zhou J; Li J; Lian H; Huang W; Guo Y; Yang S; Lin L; Cai M; Zhi C; Wu J; Liang L; Hu Y; Hu H; He J; Liang B; Zhao Q; Zhu K
    Int J Biol Sci; 2021; 17(14):3850-3861. PubMed ID: 34671203
    [No Abstract]   [Full Text] [Related]  

  • 17. Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin.
    Zheng L; Wang H; Zhou J; Shi G; Ma J; Jiang Y; Dong Z; Li J; He YQ; Wu D; Sun J; Xu C; Li Z; Wang J
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38964787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.
    Song DG; Ye Q; Poussin M; Chacon JA; Figini M; Powell DJ
    J Hematol Oncol; 2016 Jul; 9(1):56. PubMed ID: 27439908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer.
    Del Bano J; Florès-Florès R; Josselin E; Goubard A; Ganier L; Castellano R; Chames P; Baty D; Kerfelec B
    Front Immunol; 2019; 10():1593. PubMed ID: 31354732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
    Byrd TT; Fousek K; Pignata A; Szot C; Samaha H; Seaman S; Dobrolecki L; Salsman VS; Oo HZ; Bielamowicz K; Landi D; Rainusso N; Hicks J; Powell S; Baker ML; Wels WS; Koch J; Sorensen PH; Deneen B; Ellis MJ; Lewis MT; Hegde M; Fletcher BS; St Croix B; Ahmed N
    Cancer Res; 2018 Jan; 78(2):489-500. PubMed ID: 29183891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.